Immunization in midlife
DOI:
https://doi.org/10.58931/cpct.2023.1213Abstract
Midlife is often defined as age 50 and above and is a period of life when patients commonly access the healthcare system, having recognized the need for various preventions. The Women’s Health Initiative (WHI) identified cardiovascular disease (CVD), cancer and osteoporosis as the most common causes of morbidity, disability, and poor quality of life in post-menopausal women. Healthcare professionals routinely screen patients with risk factors for these diseases and offer prevention and treatment to improve their quality of life. However, recommendations for immunizations are often neglected leading to unnecessary morbidity and mortality in our aging population. In Canada, it is estimated that 20,000 hospitalizations related to influenza occur each year and that 4,000 to 8,000 Canadians die from influenza-related complications alone. Vaccines can prevent the debilitating and fatal effects of infectious disease, yet clinical evidence has revealed an adult immunization gap. Midlife screening and intervention should serve as an immunization checkpoint, providing an opportunity for healthcare professionals to optimize quality of care and health maintenance in older patients.
References
WHI Clinical Trial and Observational Study (1993-2005).
National Advisory Committee on Immunization (NACI). Statement on seasonal influenza vaccine for 2011–2012. Public Health Agency of Canada, Canada Communicable Disease Report. 2011 Oct:37(ACS-5). DOI: https://doi.org/10.14745/ccdr.v37i00a05
Stevenson CG, McArthur MA, Naus M, Abraham E, McGeer AJ. Prevention of influenza and pneumococcal pneumonia in Canadian long-term care facilities: how are we doing? CMAJ. 2001 May 15;164(10):1413-9.
US Department of Health and Human Services. Healthy People 2010: Understanding and Improving Health and Objectives for Improving Health. 2nd ed. Washington, DC: US Government Printing Office; November 2000. 2 vol.
Centers for Disease Control and Prevention (CDC). Adult vaccination coverage—United States, 2010. MMWR Morb Mortal Wkly Rep 2012 Feb;61(4):66–72.
National Vaccine Advisory Committee (NVAC). Update on the National Vaccine Advisory Committee Standards for Adult Immunization Practice. 2013 Sept 10 [accessed 2021 Mar 23]. Available from: https://www.hhs.gov/sites/default/files/nvpo/nvac/meetings/pastmeetings/2013/adult_immunization_update-sept2013.pdf
National Vaccine Advisory Committee (NVAC). 2020 National Vaccine Plan Development: recommendations from the National Vaccine Advisory Committee. Public Health Rep. 2020 Apr;135(2):181-8. DOI: https://doi.org/10.1177/0033354920904074
Nelson NP, Weng MK, Hofmeister MG, et al. Prevention of Hepatitis A Virus Infection in the United States: Recommendations of the Advisory Committee on Immunization Practices, 2020. MMWR Recomm Rep 2020;69(5):1-38. DOI: https://doi.org/10.15585/mmwr.rr6905a1
National Advisory Committee on Immunization (NACI). Update on the recommended use of Hepatitis A vaccine: an Advisory Committee Statement. Public Health Agency of Canada. 2016 May. Available from: https://www.canada.ca/en/public-health/services/publications/healthy-living/update-recommended-use-hepatitis-vaccine.html.
National Advisory Committee on Immunization (NACI). Update on the recommended use of Hepatitis B vaccine: an Advisory Committee Statement. Public Health Agency of Canada. 2017 Feb. Available from: https://www.canada.ca/en/public-health/services/publications/healthy-living/update-recommended-use-hepatitis-b-vaccine.html
Petrosky E, Bocchini Jr JA, Hariri S, Chesson H, Curtis CR, Saraiya M, Unger ER, Markowitz LE. Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the advisory committee on immunization practices. MMWR Morb Mortal Wkly Rep. 2015 Mar 3;64(11):300.
National Advisory Committee on Immunizations (NACI). Update on the recommended Human Papillomavirus (HPV) vaccine immunization schedule: an Advisory Committee Statement. Public Health Agency of Canada. 2015 Feb [accessed 2021 Mar 1]. Available from: https://publications.gc.ca/collections/collection_2015/aspc-phac/HP40-128-2014-eng.pdf.
Meites E, Szilagyi PG, Chesson HW, Unger ER, Romero JR, Markowitz LE. Human papillomavirus vaccination for adults: updated recommendations of the Advisory Committee on Immunization Practices. Am J Transplant. 2019 Nov;19(11):3202-6. DOI: https://doi.org/10.1111/ajt.15633
Kang WD, Choi HS, Kim SM. Is vaccination with quadrivalent HPV vaccine after loop electrosurgical excision procedure effective in preventing recurrence in patients with high-grade cervical intraepithelial neoplasia (CIN2-3)? Gyn Oncol. 2013;130:264-68. DOI: https://doi.org/10.1016/j.ygyno.2013.04.050
Ghelardi A, Parazzini F, Martella F, Pieralli A, Bay P, Tonetti A, Svelato A, Bertacca G, Lombardi S, Joura EA. SPERANZA project: HPV vaccination after treatment for CIN2+. Gyn Oncol. 2018 Nov 1;151(2):229-34. doi:10.1016/j.ygyno.2018.08.033 DOI: https://doi.org/10.1016/j.ygyno.2018.08.033
American Cancer Society. Cancer Facts & Figures 2021. Atlanta (GA): American Cancer Society. 2021 Jun. Available from: https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2021.html.
Merck Canada Inc. Gardasil 9 Product Monograph. 2015 Feb 5 [updated 2022 Apr 6]. Available from: https://www.merck.ca/en/wp-content/uploads/sites/20/2021/04/GARDASIL_9-PM_E.pdf
McNeil SA, Qizilbash N, Ye J, Gray S, Zanotti G, et al. A Retrospective Study of the Clinical Burden of Hospitalized All-Cause and Pneumococcal Pneumonia in Canada. Can Respir J. 2016 Mar. doi:10.1155/2016/3605834 DOI: https://doi.org/10.1155/2016/3605834
Matanock A, Lee G, Gierke R, Kobayashi M, Leidner A, Pilishvili T. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged ≥65 years: updated recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep. 2019;68:1069-75. DOI: https://doi.org/10.15585/mmwr.mm6846a5
Canadian Medical Protective Association (CMPA). How to address vaccine hesitancy and refusal by patients or their legal guardians. Ottawa (ON): Canadian Medical Protective Association. 2017 Jan.
Kroger A, Bahta L, Long S, Sanchez P. General Best Practice Guidelines for Immunization. Best Practices Guidance of the Advisory Committee on Immunization Practices (ACIP). 2017 Apr 20 [updated 2020 Nov 20].
Kobayashi M; National Center for Immunization and Respiratory Diseases (US). Considerations for age-based and risk-based use of PCV15 and PCV20 among U.S. adults and proposed policy options. Advisory Committee on Immunization Practices (ACIP) Meeting; 2021 Oct 20; Atlanta (GA). Available from: https://stacks.cdc.gov/view/cdc/110908
Kobayashi M, Bennett NM, Gierke R, Almendares O, Moore MR, Whitney CG, Pilishvili T. Intervals between PCV13 and PPSV23 vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2015 Sep 4;64(34):944-7. DOI: https://doi.org/10.15585/mmwr.mm6434a4
Wierzbowski A, Pless R, Hildebrand KJ; National Advisory Committee on Immunization (NACI). Summary of the NACI Statement on Public Health Level Recommendations on the Use of Pneumococcal Vaccines in Adults, Including the Use of 15-valent and 20-valent Conjugate Vaccines. Can Commun Dis Rep. 2023;49(2/3):81-6. DOI: https://doi.org/10.14745/ccdr.v49i23a08
Dooling KL, Guo A, Patel M, et al. Recommendations of the Advisory Committee on Immunization Practices for Use of Herpes Zoster Vaccines. MMWR Morb Mortal Wkly Rep. 2018;67:103-108. DOI: https://doi.org/10.15585/mmwr.mm6703a5
National Advisory Committee on Immunizations (NACI). Updated Recommendations on the Use of Herpes Zoster Vaccines: an Advisory Committee Statement. Public Health Agency of Canada. 2018 Jun [accessed 2021 Mar 1]. Available from: https://www.canada.ca/en/services/health/publications/healthy-living/updated-recommendations-use-herpes-zoster-vaccines.html.
Centers for Disease Control and Prevention (CDC). FDA approval of expanded age indication for a tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine. MMWR Morbid Mortal Wkly Rep. 2011;60:1279-80.
Gee J, Marquez P, Su J, et al. First Month of COVID-19 Vaccine Safety Monitoring – United States, December 14, 2020–January 13, 2021. MMWR Morb Mortal Wkly Rep. 2021;70:283-8. DOI: https://doi.org/10.15585/mmwr.mm7008e3
Oliver SE, Gargano JW, Marin M, et al. The Advisory Committee on Immunization Practices’ interim recommendation for use of Pfizer-BioNTech COVID-19 vaccine – United States, December 2020. MMWR Morb Mortal Wkly Rep. 2020;69:1922–4. DOI: https://doi.org/10.15585/mmwr.mm6950e2
Oliver SE, Gargano JW, Marin M, et al. The Advisory Committee on Immunization Practices’ interim recommendation for use of Moderna COVID-19 vaccine – United States, December 2020. MMWR Morb Mortal Wkly Rep. 2021;69:1653-6. DOI: https://doi.org/10.15585/mmwr.mm695152e1
National Advisory Committee on Immunization (NACI). Guidance on the prioritization of key populations for COVID-19 immunization. Public Health Agency of Canada. 2021 Feb 12. Available from: https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/guidance-prioritization-key-populations-covid-19-vaccination.html
American Hematology Society; Bussel JB, Connors JM, Cines DB, Dunbar CE, Michaelis LC, Baumann Kreuziger L, Lee AYY, Pabinger I. Vaccine-induced Thrombotic Thrombocytopenia. Ver 1.2 [updated 2021 Apr 23]. Available from: https://www.hematology.org/covid-19/vaccine-induced-immune-thrombotic-thrombocytopenia.
Payne JG, Tagalakis V, Wu C, Lazo-Langner A. Current estimates of the incidence of acute venous thromboembolic disease in Canada: a meta-analysis. Thromb Res. 2021 Jan;197:8-12. DOI: https://doi.org/10.1016/j.thromres.2020.10.030
National Advisory Committee on Immunization (NACI). Guidance on COVID-19 vaccine booster doses: Initial considerations for 2023. Public Health Agency of Canada. 2023 Jan 20. Available from: https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/guidance-covid-19-vaccine-booster-doses-initial-considerations-2023.html.
Grimm L, Destounis S, Dogan B, et al; Society of Breast Imaging (SBI) Patient Care and Delivery Committee. SBI Recommendations for the Management of Axillary Adenopathy in Patients with Recent COVID-19 Vaccination. 2021 Mar 9.
Shimabukuro TT, Cole M, Su JR. Reports of Anaphylaxis After Receipt of mRNA COVID-19 Vaccines in the US – December 14, 2020–January 18, 2021. JAMA. 2021;325(11):1101-2. DOI: https://doi.org/10.1001/jama.2021.1967
Klein SL, Flanagan KL. Sex differences in immune responses. Nat Rev Immunol. 2016 Aug 22;16(10):626-38. doi:10.1038/nri.2016.90 DOI: https://doi.org/10.1038/nri.2016.90
Centers for Disease Control and Prevention (CDC). Information about COVID-19 Vaccines for People who Are Pregnant or Breastfeeding. 2021 Mar 18. Available from: https://www.cdc.gov/coronavirus/2019-ncov/vaccines/recommendations/pregnancy.html.
Society of Obstetricians and Gynaecologists of Canada (SOGC), Infectious Diseases Committee. SOGC Statement on the COVID-19 vaccines and rare adverse outcomes of thrombosis associated with low platelets. 2021 Apr 21. Available from: https://sogc.org/en/content/featured-news/sogc_statement_on_the_covid-19_vaccines_and_rare_adverse_outcomes_of_%20thrombosis
Steben M, Durand N, Guichon JR, Greenwald ZR, McFaul S, Blake J. A National Survey of Canadian Physicians on HPV: knowledge, barriers, and preventive practices. J Obstet Gynaecol Can. 2019;41(5):599-607. DOI: https://doi.org/10.1016/j.jogc.2018.09.016
Steben M, Durand N, Guichon JR, Greenwald ZR, McFaul S, Blake J. A National Survey of Canadian Adults on HPV: knowledge, attitudes, and barriers to the HPV vaccine. J Obstet Gynaecol Can. 2019;41(8):1125-33. DOI: https://doi.org/10.1016/j.jogc.2019.05.005
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Canadian Primary Care Today
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
